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Abstract: Fluorescent light energy (FLE) has been used to treat various injured tissues in a non-
pharmacological and non- thermal fashion. It was applied to stimulate cell proliferation, accelerate
healing in chronic and acute wounds, and reduce pain and inflammation. FLE has been shown to
reduce pro-inflammatory cytokines while promoting an environment conducive to healing. A possible
mechanism of action of FLE is linked to regulation of mitochondrial homeostasis. This work aims
to investigate the effect of FLE on mitochondrial homeostasis in an in vitro model of inflammation.
Confocal microscopy and gene expression profiling were performed on cultures of inflamed human
dermal fibroblasts treated with either direct light from a multi-LED lamp, or FLE from either
an amorphous gel or sheet hydrogel matrix. Assessment using confocal microscopy revealed
mitochondrial fragmentation in inflamed cells, likely due to exposure to inflammatory cytokines,
however, mitochondrial networks were restored to normal 24-h after treatment with FLE. Moreover,
gene expression analysis found that treatment with FLE resulted in upregulation of uncoupling
protein 1 (UCP1) and carnitine palmitoyltransferase 1B (CPT1B) genes, which encode proteins
favoring mitochondrial ATP production through oxidative phosphorylation and lipid β-oxidation,
respectively. These observations demonstrate a beneficial effect of FLE on mitochondrial homeostasis
in inflamed cells.
Keywords: fluorescent light energy; inflammation; wound healing; mitochondria; gene expression;
mitochondrial dynamics; fluorescence
1. Introduction
Wound healing follows a series of complex overlapping processes that leads to closure of the
wound and restoration of the epithelial layer, including hemostasis, inflammation, cell proliferation
and tissue remodeling [1].
After an injury to skin, the exposed sub-endothelium, collagen and tissue factors activate
platelet aggregation to form a clot (hemostasis). Next, neutrophils appear at the site of injury to
remove debris and bacteria, promoting an environment for wound healing. Then, macrophages
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accumulate in the inflammatory phase facilitating phagocytosis of bacteria and damaged tissue. In
acute wounds, inflammation is fast and short-lived (typically 3–5 days). The inflammatory cells
orchestrate the inflammatory process and facilitate initiation of the reconstructive phase of healing.
Lamentably, in chronic non-healing wounds the inflammatory cytokines are in excess, and the
resultant pro-inflammatory environment causes degradation of growth factors and extracellular matrix
(ECM) proteins [2]. In acute wound, the proliferative phase follows the inflammatory phase, and is
characterized by accumulation of fibroblasts and production of connective tissue. Fibroblasts play a
critical role in supporting normal wound healing due to their involvement in several key processes,
including breakdown of fibrin clot, creation of new ECM and collagen structures, and contraction of
the wound [3]. Finally, during the tissue remodeling phase, collagen bundles are reorganized, restoring
epidermal barrier function and skin integrity. Overall, the healing process involves numerous cellular
and biosynthetic processes, which all require energy in the form of adenosine triphosphate (ATP),
as well as amino acids, and other precursor molecules to replace damaged tissue [4–6].
Mitochondria are the key organelles responsible for ATP production in human cells, generating
energy through oxidative phosphorylation [7]. The mitochondrial respiratory chain consists of a
five-subunit complex (I-V) through which electrons are exchanged at increasing reduction potentials,
leading to production of ATP [8]. Besides production of ATP for cellular energy, mitochondria also
generate reactive oxygen species (ROS) as a by-product of ATP formation [9]. The role of ROS in
wound healing is complex. ROS contributes to the oxidative burst that kills bacteria, and acts as a
cell signal to increase cell proliferation, which is vital in wound repair [10]. However, ROS are also
very potent molecules and can cause damage to DNA, lipids and proteins [11]. Excessive levels of
ROS have been associated with chronic wounds, resulting in tissue damage, excessive inflammation,
and delayed healing [12,13]. Furthermore, high levels of oxidative stress impact on mitochondrial
morphology and positioning within cells, causing mitochondria to cluster around the nucleus as a
protective strategy [14,15].
Generally, mitochondria undergo a constant process of fission and fusion where they join and
subsequently split back into separate entities. This process is thought to be a housekeeping effect to
ensure that mitochondria stay as efficient as possible [16]. The position of mitochondria within cells is
dynamic based on localized signals or energy balance. For instance, during cell migration mitochondria
will locate close to the migrating cell edges where rapid reorganization of the cytoskeleton filaments
requires more ATP for energy [17–19].
Photobiomodulation (PBM) is the term used to describe the application of low-level light energy
to induce tissue regeneration or to protect tissue that is injured or degenerating [20–22]. PBM has
been shown to be effective in accelerating healing in chronic and acute wounds [23,24], as well as
reducing pain and inflammation in several conditions [25–27]. Moreover, PBM reverses toxic effects of
neurotoxins, stimulates stem cell proliferation, and displays therapeutic effects in reducing myocardial
ischemia reperfusion related to myocardial injury [28,29].
One of the most well-studied mechanisms of PBM is the ability to interact with endogenous
chromophores in tissue that absorb photons (light). The most studied endogenous chromophore
is complex IV of the mitochondrial respiratory chain, cytochrome c oxidase (CCO). Studies have
shown that the activation spectrum of CCO runs from yellow through to red wavelengths (~570–910
nm). Absorption of photons by CCO initiates a biochemical cascade that increases ATP and ROS
generation within the electron transport chain [30–33]. Additionally, evidence suggests that one
possible mechanism of action of photons on the wound healing process is regulation of the homeostatic
balance between mitochondrial fusion and fission [34]. Mitochondria fusion helps reduce mitochondrial
stress by mixing the contents of partially damaged mitochondria. Fission allows the creation of new
mitochondria, but it also enables the removal of damaged mitochondria [35].
A form of PBM is fluorescent light energy (FLE) that acts as a vehicle to induce biomodulation.
To generate fluorescence, specialized chromophores (light absorbing molecules) are employed to
translate light energy into a low-energy emission of fluorescence through a mechanism known as
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stokes shift [36]. FLE is a unique form of photobiomodulation that has been demonstrated to advance
healing of both acute and chronic wounds [37,38]. Studies have demonstrated that acute incisional
wounds have reduced inflammation, as well as more physiologic re-epithelization and collagen
remodeling resulting in better quality and less visible scars [25–27,39]. Additionally, patients with
hard-to-heal chronic ulcers experienced accelerated healing and improved quality of life [23]. These
studies have documented the safety and efficacy of FLE in a variety of impaired skin conditions [40].
The beneficial impact of FLE on inflammation has been well documented, with improved inflammatory
profiles observed in clinical trials for wound healing [37], acne treatment [41], and management of
rosacea [42], as well as in canine pyoderma [43] and mechanistic in vitro studies [36]. These studies
have demonstrated that FLE has the ability to reduce pro-inflammatory cytokines produced by human
dermal fibroblasts (HDFs), as well as increase levels of some anti-inflammatory cytokines, which have
a beneficial effect in the treatment of chronic wounds that are stuck in an inflammatory feedback
loop [36].
The effect of FLE on mitochondrial homeostasis is still largely unknown. We tested the effect of
FLE on an in vitro model of inflammation. Cultures of normal HDFs were stimulated with a cocktail of
pro-inflammatory cytokines to create inflamed cells. These inflamed cells were treated with either direct
light (photobiomodulation) or FLE. Two forms of photoconverter substrates were tested: an amorphous
gel (FLE-Gel) or sheet hydrogel matrix (FLE-Matrix). Variations in the mitochondrial network were
analyzed with confocal microscopy. Expression profiles of genes related to mitochondrial dynamic,
biogenesis and function were assessed by PCR gene array. Confocal microscopy showed the presence
of mitochondrial fragmentation due to exposure to the inflammatory cytokines, but a restoration of
the mitochondrial network 24 h post-treatments was observed, in particular in cultures treated with
FLE. The gene expression analysis showed that treatment with FLE-Matrix upregulated UCP1 and
CPT1B genes, which encode proteins that favor ATP production through oxidative phosphorylation
and lipid β-oxidation, respectively. Treatment with FLE-Gel upregulated SLC25A31 gene, linked to
cytosolic adenosine diphosphate (ADP) balance. These observations, together with the already known
capacity of photobiomodulation to stimulate cytochrome c oxidase, show a beneficial effect of FLE in
the treatment of inflamed wounds.
2. Experimental Section
2.1. Cell Culture Preparation
Normal human dermal fibroblasts (HDFs; PCS-201-012, American Type Culture Collection (ATCC,
Manassas, VA, USA) were cultured at 37 ◦C and 5% CO2 in Fibroblast Basal Medium (phenol red-free;
ATCC, Manassas, VA, USA) supplemented with Fibroblast Growth Kit-Low serum (ATCC, Manassas,
VA, USA). The culture process was performed seeding HDFs in 6-well plastic plates at a density of
10 × 104 cell/well. Healthy cells were incubated in basal medium for the duration of the experiment.
Inflamed cells (including all treatment groups) were incubated for 5–6 h in basal medium prior to
inducing an in vitro inflammatory state with an 18-h incubation in an inflammatory cocktail comprising
20 ng/mL each of pro-inflammatory cytokines recombinant human tumor necrosis factor alpha (TNF-α;
Miltenyi Biotec S.r.l., Bologna, Italy) and recombinant human Interleukin-1 beta (IL-1β; Miltenyi
Biotec S.r.l.).
For all treatment groups (Light, FLE-Gel, and FLE-Matrix), after the 18-h incubation in the
inflammatory cocktail, the media was replaced with Phosphate Buffer Saline (PBS; Euroclone S.p.A.,
Italy) for the illumination procedure (5-min) to minimize scattering or other interference with the light.
After the illumination, the PBS was replaced with fresh media containing the TNFα/IL-1β inflammatory
cocktail to continue with the inflammatory stimulus. Untreated inflamed HDFs were also placed in
PBS for 5 min (to mimic the treatment conditions), and then were incubated in fresh media containing
inflammatory cockail for the duration of the experiment.
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Mitochondrial morphology was analyzed at 30-min and 24-h post-treatment for all groups, and
gene expression profile was investigated at 6-h post-treatment.
2.2. Fluorescent Light Energy (FLE) Systems
FLE Systems consist of a multi-LED lamp (KT-L lamp, Klox Technologies Inc., Laval, QC, Canada)
and a topical photoconverter substrate in the form of an amorphous gel (FLE-Gel) or sheet hydrogel
matrix (FLE-Matrix) (LumiHealTM Gel and LumiHealTM Matrix, Klox Technologies Inc., Laval, QC,
Canada). The multi-LED lamp delivers non-coherent light between 400–520 nm with a peak at app.
447 nm and a power density between 110–150 mW/cm2 at a distance of 5 cm from the light-emitting
diodes (LEDs). The lamp is equipped with a 5-min timer and a distance indicator. FLE photoconverters
contain a chromophore, embedded within the gel or matrix, which can absorb some of the photons
from the multi-LED lamp, and emit FLE in the range of approximately 510–700 nm. Thus cells treated
with FLE receive a combination of direct light from the multi-LED lamp plus FLE emitted from the
Gel or Matrix photoconverter, for delivery of a full spectral range between 400–700 nm. Of note, a
dose response for FLE may be observed by assessing FLE-Gel compared with FLE-Matrix, as FLE-Gel
generates 0.1–0.2 J/cm2 of fluorescence (~510–700 nm) whereas FLE-Matrix generates 0.2–0.7 J/cm2.
2.3. Fluorescence Light Energy (FLE) Protocols
Three treatment conditions were tested in order to study the impact of FLE on mitochondrial
morphology and gene expression. Light-treated cells received a 5-min illumination with the multi-LED
lamp placed 5 cm from the bottom of the plate, without the presence of a topical photoconverter. For
FLE-treated cells (FLE-Gel or FLE-Matrix) the topical photoconverters were placed under the 6-well
plate, not in direct contact with cells, and the multi-LED lamp was placed at 5 cm from the bottom
of the plate. Light and FLE are transmitted unchanged through the plastic bottom of the plate, thus
contact with the cells is not required to induce their effects. The illumination duration was 5-min for all
treatment groups. Each of the following groups were tested:
(a) Healthy: HDFs maintained in basal medium (no inflammatory cocktail or illumination).
(b) Inflamed: HDFs incubated in TNFα/IL-1β inflammatory cocktail.
(c) Light: Inflamed HDFs illuminated for 5-min with only the multi-LED lamp (no FLE).
(d) Gel: Inflamed HDFs illuminated for 5-min with the FLE-Gel system consisting of the multi-LED
lamp and topical photoconverter amorphous gel (LumiHeal Gel, Klox Technologies Inc., Laval,
QC, Canada).
(e) Matrix: Inflamed HDFs illuminated for 5-min with the FLE-Matrix system consisting of the
multi-LED lamp and topical photoconverter sheet hydrogel matrix (LumiHeal Matrix, Klox
Technologies Inc., Laval, QC, Canada).
Healthy HDFs were considered as the control group of the experiment.
2.4. Mitochondrial Morphology
Cells were seeded in coverslips 24-mm in diameter and allowed to grow to a confluence of 50–60%.
After treatments, cells were fixed with 4% paraformaldehyde solution (Sigma-Aldrich, USA) and
washed three-times. Next, cells were permeabilized with a solution of 0.1% triton x-100 (Sigma-Aldrich,
USA), for 10 min at room-temperature (RT) on a plate-shaker. After three-washes, unspecific sites
were blocked with a solution of 2% bovine serum albumin (Sigma-Aldrich, USA) supplemented
of 0.01% triton x-100 for 45 min. at RT with agitation. Cells were next incubated with a primary
antibody against TOM20 (mitochondrial marker of the inner membrane) (BD, USA) diluted 1:100
over-night at 4 ◦C. The next day, cells were washed with three washes of 10 min each with agitation
at RT and next incubated with a specific secondary fluorescent antibody Alexa Fluor 488 (Thermo
Fisher Scientific, Waltham, USA) diluted 1:1000 in the dark for 45 min at RT with agitation. Cells were
acquired in z-stacks of 51 planes at 0.2 µm each at Nikon A1 confocal microscope equipped with a
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63X objective. Images obtained were deconvolved to remove blurred signal and 3D reconstructed.
The mitochondrial network was then quantified by using the 3D-object counter available in software
Fiji (http://fiji.sc/wiki/index.php/Fiji accessed on 29 April 2017) that allow to measure the total object
(mitochondria) volume and the number of total objects (mitochondria) per each cell. The mean volume
of single mitochondria was calculated by divide the total mitochondria volume with the number of
total mitochondria. For each condition, at least 20 cells were analyzed. Data are presented as mean
± SD. Multi comparison statistical analyses were performed by using one-way ANOVA. T test was
to perform all pairwise comparisons between group means. Calculated mean ± SD are reported in
figure legends.
2.5. Total RNA Isolation and PCR Array Profile
As previously described [44], total RNA was extracted by the RNeasy Mini Kit (Qiagen, Hilden
Germany) which includes DNase digestion using the RNase-Free DNase Set (Qiagen). For each
sample, 500 ng of total RNA were reverse transcribed with RT2 First Strand Kit (Qiagen) in SimpliAmp
Thermal Cycler (Thermo Fisher Scientific) following the manufacture procedures. Then, the RT2
Profiler PCR Array Human Mitochondrial Energy Metabolism (Qiagen) and RT2 Profiler PCR Array
Human Mitochondria (Qiagen) in StepOne Plus Real-Time PCR System (Thermo Fisher Scientific)
were performed. The amplification protocol included the activation at 95 ◦C for 10 min, followed by 40
cycles of denaturation at 95 ◦C for 15 s, and elongation at 60 ◦C for 1 min. The 2∆∆CT method was
used to determine the relative expression of target genes. Cycle threshold (Ct) values of target genes
were normalized to the geometric mean Ct values of five housekeeping genes (ACTB: actin, beta; B2M:
beta-2-microglobulin; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HPRT1: hypoxanthine
phosphoribosyl transferase 1; RPLP0: ribosomal protein, large, P0). For each target gene, the average
of three normalized expression levels were calculated, and p values were calculated using Student’s
t-test based on 2∆CT values for each gene in the test group compared to the control group. Statistical
significance was set at p < 0.05. Results were reported as fold regulation of target genes in test group
compared with control group.
3. Results
3.1. Mitochondrial Morphology Analysis
Analysis of the mitochondrial morphology was performed in all HDF conditions: (a) healthy
HDFs in normal media (Healthy), (b) inflamed HDFs in TNFα/IL-1β inflammatory cocktail (Inflamed),
(c) inflamed HDFs treated with light alone (Light), (d) inflamed HDFs treated with FLE-Gel (Gel),
and (e) inflamed HDFs treated with FLE-Matrix (Matrix). Importantly, incubation of HDFs with
the TNFα/IL-1β inflammatory cocktail led to fragmentation of the mitochondrial network (Figure 1).
A global reduction of mitochondrial volume per cell was observed in Inflamed HDFs (Figure 1a)
accompanied by an increase in the number of mitochondria per cell, and a reduction of individual
mitochondrion volume (Figure 1b,c, respectively). Predictably, greater exacerbation of the mitochondria
was observed in Inflamed HDFs at 24 h compare to 30 min, due to the continued exposure to the
inflammatory cocktail (Figure 2).
Interestingly, when inflamed cells were exposed to either direct light (Light) or FLE (Gel or Matrix)
the mitochondrial network showed preliminary signs of improvement at 30-min post-treatment, with
some statistical differences already observed in FLE-treated cells. This improvement occurred despite
the continued exposure to the TNFα/IL-1β inflammatory cocktail. Mitochondrial number per cell in
Inflamed HDFs was 51 ± 13, compared with 41 ± 11 in FLE-Gel HDFs (p = 0.019) and 41 ± 12 in FLE
Matrix HDFs (p = 0.0148). Similarly, individual mitochondrion volume was 12.8 ± 4.13 µm3 in Inflamed
HDFs, compared with 18.3 ± 6.5 µm3 (p = 0.0185) and 18.6 ± 6.3 µm3 (p = 0.0156) in FLE-Gel and
FLE-Matrix HDFs, respectively. Taken together, this data indicates that mitochondria in FLE-treated
cells have shifted their mitochondrial network into a more fused state, with larger mitochondria that
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are fewer in number. While the difference in the volume of the entire mitochondrial network per
cell did not reach significance between Inflamed and FLE-treated cells at the 30 min time point, it is
interesting to note that while both Inflamed and Light-treated HDFs are different from Healthy HDFs
(648 ± 237 µm3 and 639 ± 273 µm3 vs. 840 ± 153 µm3, p = 0.0103 and 0.0093 respectively), neither of
the FLE-treated groups were significantly different from Healthy HDFs, suggesting they are already
starting to recover from the inflamed state.
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Figure 1. Quantification of mitochondrial network 30-min post-treatment. After deconvolution, images
were 3D reconstructed and the mitochondrial network was evaluated by automated estimation of (a)
volume of the entire mitochondrial network per single cell, (b) number of mitochondria per single cell,
and (c) volume of single mitochondrion. Data are expressed as mean ± SD. Multi comparison statistical
analysis were performed by using one-way analysis of variance (ANOVA). T tests were performed on all
pairwise comparisons between group means. * p < 0.05 from Healthy human dermal fibroblasts (HDFs),
† < 0.05 from Inflamed human dermal fibroblasts (HDFs), ns = not significant. (d) Representative
images. FLE: fluorescent light energy.
In order to verify this possibility, the healthiness of the mitochondrial network was analyzed
for a longer period of time. At 24-h post-treatment Inflamed HDFs treated with FLE had completely
recovered to healthy-HDF mitochondrial morphology, while cells treated with Light were only partially
recovered (Figure 2). All observed aspects of the mitochondrial networks were significantly improved
in FLE-treated cells compared with Inflamed HDFs. Volume of the entire mitochondrial network
per cell was 802 ± 133 µm3 in FLE-Gel HDFs, and 910 ± 159 µm3 in FLE-Matrix, compared with
523 ± 301 µm3 in Inflamed HDFs (p = 0.0018 and 0.0001, respectively). Values for the FLE-treated
cells were not significantly different from Healthy HDFs (845 ± 205 µm3). Additionally, the count
of mitochondria number per cell for Inflamed HDFs was 57 ± 16 compared with 48 ± 14 and 39 ± 9
for FLE-Gel and FLE-Matrix (p = 0.0016 and p = 0.0001, respectively), and individual mitochondrion
volume was 9.5 ± 3.5 µm3 in Inflamed HDFs compared with 20 ± 5.6 µm3 and 24 ± 7.5 µm3 for FLE-Gel
and FLE-Matrix (p = 0.0016 and p = 0.0001, respectively). By comparison, Light-treatment had induced
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some recovery, and was no longer significantly different from healthy HDFs in any parameter. However,
it was only significantly improved compared with Inflamed cells in the individual mitochondrion
volume (10 ± 3 vs. 16 ± 4 µm3 for Inflamed vs. Light respectively, p = 0.0104).
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volume of the entire mitochondrial network per single cell, (b) number of mitochondria per single 
cell, and (c) volume of single mitochondrion. Data are expressed as mean ± SD. Multi comparison 
statistical analysis were performed by using one-way analysis of variance (ANOVA). T test was to 
perform all pairwise comparisons between group means. * p < 0.05 from Healthy human dermal 
fibroblasts (HDFs), † < 0.05 from Inflamed human dermal fibroblasts (HDFs), ns = not significant. (d) 
Representative images. FLE: fluorescent light energy. 
In Figure 3, radial graphs provide a visual representation of the ability of FLE to fully rescue the 
mitochondrial dynamics of inflamed HDFs. All values are indexed to the healthy values for volume 
of the mitochondrial network per cell (top, Mitochondria Volume per cell, MV/c), number of 
mitochondria per cell (bottom right, Mitochondria Number per cell, MN/c) and individual 
mitochondrion volume (bottom left, Individual Mitochondrion Volume, IMV). The green line 
represents the Healthy condition, and the red line indicates the Inflamed status. At both the 30-min 
(Figure 2a) and 24-h (Figure 2b) post-treatment time points, it is apparent that Light-treated cells (blue 
lines) are shifting away from the Inflamed state towards the Healthy condition. A noticeably greater 
recovery is visible in FLE-treated cells (FLE-Gel in yellow and FLE-Matrix in orange) at 30-min post-
treatment, where both have already progressed beyond the Light cells toward the Healthy condition. 
Impressively, by 24-h post-treatment FLE-treated cells are completely recovered, even overlapping 
with the Healthy condition. 
Figure 2. Quantification of mitochondrial network 24-h post-treatment. After deconvolution, images
were 3D reconstructed and the mitochondrial network was evaluated by automated estimation of (a)
volume of the entire mitochondrial network per single cell, (b) number of mitochondria per single cell,
and (c) volume of single mitochondrion. Data are expressed as mean ± SD. Multi comparison statistical
analysis were performed by using one-way analysis of variance (ANOVA). T test was to perform all
pairwise comparisons between group means. * p < 0.05 from Healthy human dermal fibroblasts (HDFs),
† < 0.05 from Inflamed human dermal fibroblasts (HDFs), ns = not significant. (d) Representative
images. FLE: fluorescent light energy.
In Figure 3, radial graphs provide a visual representation of the ability of FLE to fully rescue the
mitochondrial dynamics of inflamed HDFs. All values are indexed to the healthy values for volume of
the mitochondrial network per cell (top, Mitochondria Volume per cell, MV/c), number of mitochondria
per cell (bottom right, Mitochondria Number per cell, MN/c) and individual mitochondrion volume
(bottom left, Individual Mitochondrion Volume, IMV). The green line represents the Healthy condition,
and the red line indicates the Inflamed status. At both the 30-min (Figure 2a) and 24-h (Figure 2b)
post-treatment time points, it is apparent that Light-treated cells (blue lines) are shifting away from the
Inflamed state towards the Healthy condition. A noticeably greater recovery is visible in FLE-treated
cells (FLE-Gel in yellow and FLE-Matrix in orange) at 30-min post-treatment, where both have already
progressed beyond the Light cells toward the Healthy condition. Impressively, by 24-h post-treatment
FLE-treated cells are completely recovered, even overlapping with the Healthy condition.
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Figure 3. Radial graphs depicting relative changes in mitochondrial networks at (a) 30-min and (b) 24-h
post-treatment. All parameters are indexed to Healthy-HDFs (green). Inflamed-HDFs are depicted in
red, Light-treated HDFs in blue, FLE-Gel in yellow, and FLE-Matrix in orange. At time point 30-min
the FLE-Gel (yellow) and FLE-Matrix (Orange) overlap, and at time point 24-h the Healthy (green) and
FLE-Gel (yellow) overlap. MV/c = Mitochondria Volume per cell; MN/c = Mitochondria Number per cell;
IMV = Individual Mitochondrion Volume.
3.2. PCR Array Gene Expression Profile
In order to investigate the biological impact of the treatments on mitochondrial dynamic and
function, mitochondrial gene expression was probed with two different real-time PCR array, measured
6-h post-treatment.
Table 1 presents data on the expression of 84 key genes associated with mitochondrial respiration,
including genes encoding components of the electron transport chain and oxidative phosphorylation
complexes. Oxidation of Nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide
(FADH2), key metabolites in glycolysis and the citric acid cycle, occurs within a series of four
protein complexes embedded in the inner mitochondrial membrane: NADH-coenzyme Q reductase,
succinate-coenzyme Q reductase, coenzyme Q-cytochrome c reductase, and CCO. The free energy
generated from these processes drives oxidative phosphorylation and ATP synthesis via a fifth protein
complex (ATP synthase) [45].
Table 1. Human Mitochondrial Energy Metabolism PCR array.






vs. Inflamed p Value
ATP12A 1.08 0.3024 1.31 0.5219 −1.11 0.1645 1.02 0.1648
ATP4A 2.23 0.7832 1.03 0.6392 −1.03 0.2884 −1.03 0.2967
ATP4B 1.45 0.3082 1.79 0.7798 −1.21 0.2096 1.52 0.2148
ATP5A1 −1.08 0.9484 −1.14 0.9730 1.06 0.7168 1.03 0.8362
ATP5B −1.05 0.9663 −1.04 0.9969 1.00 0.9906 1.04 0.5569
ATP5C1 −1.05 0.9517 −1.12 0.9898 −1.08 0.8672 −1.04 0.9454
ATP5F1 −1.23 0.1785 1.01 0.2102 1.05 0.1455 1.07 0.1458
ATP5G1 −1.02 0.8216 1.01 0.9565 −1.05 0.1904 1.02 0.2007
ATP5G2 −1.15 0.8984 1.28 0.9757 1.28 0.2901 1.08 0.2901
ATP5G3 −1.04 0.2888 −1.02 0.8484 −1.09 0.1986 −1.04 0.1983
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vs. Inflamed p Value
ATP5H −1.13 0.4352 1.05 0.7275 1.14 0.2591 1.08 0.2589
ATP5I −1.08 0.9752 1.05 0.8689 −1.05 0.8167 0.99 0.9525
ATP5J 1.02 0.9968 −1.02 0.9737 −1.04 0.9612 0.99 0.9791
ATP5J2 −1.23 0.9810 −1.07 0.9603 −1.01 0.2836 1.22 0.2834
ATP5L 1.68 0.5228 −1.36 0.8836 −1.53 0.2096 −1.27 0.2134
ATP5O −1.24 0.8745 1.05 0.7809 −1.03 0.8725 −1.04 0.5821
ATP6V0A2 2.59 0.9270 1.03 0.3655 −1.79 0.2746 −1.09 0.1516
ATP6V0D2 1.91 0.6030 1.62 0.9800 1.36 0.2356 1.21 0.4197
ATP6V1C2 1.11 0.1784 1.12 0.6929 −1.18 0.2758 1.20 0.2789
ATP6V1E2 1.02 0.6367 1.01 0.8071 1.17 0.1381 1.04 0.1352
ATP6V1G3 −1.70 0.4560 1.12 0.8299 −1.11 0.3228 −1.05 0.3231
BCS1L −1.46 0.5451 −1.07 0.8080 1.16 0.4274 1.24 0.4942
COX4I1 1.08 0.6312 −1.02 0.6719 1.03 0.7022 1.06 0.7194
COX4I2 −1.85 0.9443 3.24 0.8211 1.40 0.1855 1.90 0.1854
COX5A −1.15 0.9779 −1.02 0.3636 −1.05 0.1026 1.10 0.0556
COX5B −1.08 0.8219 1.06 0.6803 1.01 0.6248 1.01 0.6164
COX6A1 1.05 0.9912 −1.02 0.6452 −1.05 0.9001 −1.06 0.8699
COX6A2 1.29 0.7882 1.55 0.4056 −1.03 0.5157 −1.02 0.3269
COX6B1 1.09 0.8830 1.06 0.3851 −1.12 0.3845 −1.06 0.1568
COX6B2 1.54 0.6464 1.36 0.9643 −1.06 0.2774 1.21 0.2775
COX6C −2.23 0.2374 1.12 0.4507 −1.11 0.2241 1.18 0.2246
COX7A2 1.31 0.8657 1.00 0.7080 1.00 0.2980 1.02 0.3576
COX7A2L 1.14 0.9597 1.18 0.3701 −1.02 0.2149 1.02 0.2810
COX7B −1.23 0.1399 1.03 0.9086 −1.11 0.8089 −1.07 0.8180
COX8A −1.02 0.6213 1.04 0.7314 −1.01 0.3849 1.03 0.4075
COX8C 1.11 0.3632 3.60 0.3340 −1.20 0.2921 1.67 0.2925
CYC1 1.03 0.9564 1.02 0.9543 −1.01 0.8904 1.00 0.8846
LHPP −1.12 0.7322 1.14 0.6447 1.10 0.9146 1.02 0.9953
NDUFA1 1.07 0.6609 −1.06 0.7084 1.06 0.2131 −1.16 0.2167
NDUFA10 −1.06 0.9250 0.99 0.7389 1.01 0.6267 0.99 0.7675
NDUFA11 −1.03 0.9466 −1.02 0.9339 1.04 0.8978 1.09 0.9636
NDUFA2 1.07 0.9914 1.02 0.3434 1.11 0.1150 1.01 0.0749
NDUFA3 −1.29 0.8155 1.05 0.9753 −1.04 0.8924 −1.03 0.8893
NDUFA4 1.09 0.5712 1.03 0.7243 −1.04 0.0812 −1.04 0.0819
NDUFA5 −1.97 0.5816 1.28 0.9752 −1.24 0.2903 1.15 0.3374
NDUFA6 1.03 0.1884 −1.07 0.5686 1.18 0.1108 1.12 0.1032
NDUFA7 −1.03 0.9399 −1.03 0.9026 1.04 0.3395 1.00 0.2997
NDUFA8 −1.23 0.8994 −1.08 0.7818 1.23 0.8069 0.99 0.4317
NDUFAB1 1.08 0.5897 1.03 0.9813 −1.03 0.7660 −1.04 0.7574
NDUFB10 −1.03 0.2064 −1.03 0.6846 1.00 0.7707 −1.02 0.7615
NDUFB2 −1.15 0.9577 1.05 0.2898 1.05 0.1720 −1.05 0.3253
NDUFB3 −1.14 0.8127 1.03 0.8891 1.07 0.3763 −1.03 0.3061
NDUFB4 1.24 0.3245 −1.06 0.7046 1.09 0.0957 1.04 0.0861
NDUFB5 −1.07 0.5122 1.04 0.1030 1.05 0.0993 1.03 0.0712
NDUFB6 −1.08 0.6834 1.09 0.3958 −1.07 0.4169 −1.21 0.1946
NDUFB7 −1.25 0.8837 1.03 0.9139 1.07 0.9146 1.11 0.9221
NDUFB8 −1.29 0.9782 −1.08 0.4260 1.04 0.0860 1.04 0.0867
NDUFB9 −1.07 0.8154 1.04 0.6321 −1.03 0.3974 1.00 0.3031
NDUFC1 −1.13 0.6376 1.06 0.4091 1.10 0.1097 −1.03 0.1077
NDUFC2 1.03 0.6633 1.03 0.5582 1.26 0.4491 1.21 0.6712
NDUFS1 −1.05 0.8937 1.03 0.8077 1.06 0.2821 1.06 0.2782
NDUFS2 −1.05 0.6046 1.08 0.8433 1.08 0.5569 1.05 0.5270
NDUFS3 1.14 0.7629 −1.09 0.3173 1.05 0.1314 1.05 0.0777
NDUFS4 −1.11 0.3228 1.05 0.6511 −1.01 0.6848 −1.04 0.5687
NDUFS5 −1.13 0.9234 1.05 0.8181 1.01 0.3283 −1.03 0.4957
NDUFS6 −1.10 0.7346 1.09 0.9146 1.05 0.6572 1.11 0.6882
NDUFS7 −1.29 0.7148 −1.32 0.7148 1.05 0.3395 1.02 0.2788
NDUFS8 −1.23 0.8670 1.03 0.9886 1.18 0.9448 1.23 0.9275
NDUFV1 −1.21 0.8922 0.99 0.6639 1.04 0.1205 1.06 0.1277
NDUFV2 −1.21 0.8671 1.08 0.5305 1.06 0.1460 −1.02 0.2872
NDUFV3 1.13 0.7272 −1.10 0.3081 1.26 0.1167 1.24 0.1145
OXA1L −1.13 0.5362 1.14 0.5885 1.27 0.1040 1.22 0.1026
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vs. Inflamed p Value
PPA1 −1.71 0.2951 −1.03 0.5926 1.04 0.8757 −1.02 0.8405
PPA2 −1.19 0.5189 1.04 0.4868 −1.02 0.2007 −1.04 0.2018
SDHA −1.42 0.3281 1.09 0.5285 1.05 0.1407 1.02 0.1423
SDHB 1.04 0.5917 1.01 0.8479 1.04 0.6252 1.03 0.7692
SDHC −1.19 0.7466 1.22 0.6577 −1.05 0.1798 −1.02 0.1799
SDHD −1.22 0.8702 −1.23 0.9003 1.00 0.5197 −1.07 0.7193
UQCR11 1.26 0.4176 −1.16 0.8663 −1.04 0.1969 −1.06 0.1947
UQCRC1 −1.03 0.9857 −1.13 0.8575 −1.02 0.9116 −1.04 0.8919
UQCRC2 −1.29 0.8090 −1.21 0.1460 1.02 0.1357 1.04 0.1405
UQCRFS1 −1.03 0.9645 −1.17 0.8910 −1.03 0.9580 −1.03 0.9512
UQCRH −1.03 0.9254 −1.07 0.9792 −1.04 0.9931 −1.04 0.9962
UQCRQ 1.00 0.5753 −1.11 0.7945 1.06 0.8875 1.03 0.8636
ATP12A: ATPase, H+/K+ transporting, nongastric, alpha polypeptide; ATP4A: ATPase, H+/K+ exchanging, alpha
polypeptide; ATP4B: ATPase, H+/K+ exchanging, beta polypeptide; ATP5A1: ATP synthase, H+ transporting,
mitochondrial F1 complex, alpha subunit 1, cardiac muscle; ATP5B: ATP synthase, H+ transporting, mitochondrial
F1 complex, beta polypeptide; ATP5C1: ATP synthase, H+ transporting, mitochondrial F1 complex, gamma
polypeptide 1; ATP5F1: ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1; ATP5G1: ATP
synthase, H+ transporting, mitochondrial Fo complex, subunit C1; ATP5G2: ATP synthase, H+ transporting,
mitochondrial Fo complex, subunit C2; ATP5G3: ATP synthase, H+ transporting, mitochondrial Fo complex,
subunit C3; ATP5H: ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d; ATP5I: ATP synthase,
H+ transporting, mitochondrial Fo complex, subunit E; ATP5J: ATP synthase, H+ transporting, mitochondrial
Fo complex, subunit F6; ATP5J2: ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2; ATP5L:
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G; ATP5O: ATP synthase, H+ transporting,
mitochondrial F1 complex, O subunit; ATP6V0A2: ATPase, H+ transporting, lysosomal V0 subunit a2; ATP6V0D2:
ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d2; ATP6 V1C2: ATPase, H+ transporting, lysosomal 42
kDa, V1 subunit C2; ATP6V1E2: ATPase, H+ transporting, lysosomal 31 kDa, V1 subunit E2; ATP6V1G3:ATPase,
H+ transporting, lysosomal 13 kDa, V1 subunit G3; BCS1L: BCS1-like (S. cerevisiae); COX4I1: Cytochrome c oxidase
subunit IV isoform 1; COX4I2: Cytochrome c oxidase subunit IV isoform 2; COX5A: Cytochrome c oxidase subunit
Va; COX5B: Cytochrome c oxidase subunit Vb; COX6A1: Cytochrome c oxidase subunit VIa polypeptide 1; COX6A2:
Cytochrome c oxidase subunit VIa polypeptide 2; COX6B1: Cytochrome c oxidase subunit Vib polypeptide 1;
COX6B2: Cytochrome c oxidase subunit VIb polypeptide 2; COX6C: Cytochrome c oxidase subunit Vic; COX7A2:
Cytochrome c oxidase subunit VIIa polypeptide 2; COX7A2L: Cytochrome c oxidase subunit VIIa polypeptide 2 like;
COX7B: Cytochrome c oxidase subunit VIIb; COX8A: Cytochrome c oxidase subunit VIIIA; COX8C: Cytochrome c
oxidase subunit VIIIC; CYC1: Cytochrome c-1; LHPP: Phospholysine phosphohistidine inorganic pyrophosphate
phosphatase; NDUFA1: NADH dehydrogenase 1 alpha subcomplex, 1, 7.5 kDa; NDUFA10: NADH dehydrogenase
1 alpha subcomplex, 10, 42 kDa; NDUFA11: NADH dehydrogenase 1 alpha subcomplex, 11, 14.7 kDa; NDUFA2:
NADH dehydrogenase 1 alpha subcomplex, 2, 8 kDa; NDUFA3: NADH dehydrogenase 1 alpha subcomplex,
3, 9 kDa; NDUFA4: NADH dehydrogenase 1 alpha subcomplex, 4, 9 kDa; NDUFA5: NADH dehydrogenase 1
alpha subcomplex, 5, 13 kDa; NDUFA6: NADH dehydrogenase 1 alpha subcomplex, 6, 14 kDa; NDUFA7: NADH
dehydrogenase 1 alpha subcomplex, 7, 14.5 kDa; NDUFA8: NADH dehydrogenase 1 alpha subcomplex, 8, 19
kDa; NDUFAB1: NADH dehydrogenase 1, alpha/beta subcomplex, 1, 8 kDa; NDUFB10: NADH dehydrogenase 1
beta subcomplex, 10, 22 kDa; NDUFB2: NADH dehydrogenase 1 beta subcomplex, 2, 8 kDa; NDUFB3: NADH
dehydrogenase 1 beta subcomplex, 3, 12 kDa; NDUFB4: NADH dehydrogenase 1 beta subcomplex, 4, 15 kDa;
NDUFB5: NADH dehydrogenase 1 beta subcomplex, 5, 16 kDa; NDUFB6: NADH dehydrogenase 1 beta subcomplex,
6, 17 kDa; NDUFB7: NADH dehydrogenase 1 beta subcomplex, 7, 18 kDa; NDUFB8: NADH dehydrogenase 1
beta subcomplex, 8, 19 kDa; NDUFB9: NADH dehydrogenase 1 beta subcomplex, 9, 22 kDa; NDUFC1: NADH
dehydrogenase 1, subcomplex unknown, 1, 6 kDa; NDUFC2: NADH dehydrogenase 1, subcomplex unknown, 2,
14.5 kDa; NDUFS1: NADH dehydrogenase Fe-S protein 1, 75 kDa; NDUFS2: NADH dehydrogenase Fe-S protein 2,
49 kDa; NDUFS3: NADH dehydrogenase Fe-S protein 3, 30 kDa; NDUFS4: NADH dehydrogenase Fe-S protein 4,
18 kDa; NDUFS5: NADH dehydrogenase Fe-S protein 5, 15 kDa; NDUFS6: NADH dehydrogenase Fe-S protein 6,
13 kDa; NDUFS7: NADH dehydrogenase Fe-S protein 7, 20 kDa; NDUFS8: NADH dehydrogenase Fe-S protein 8,
23 kDa; NDUFV1: NADH dehydrogenase flavoprotein 1, 51 kDa; NDUFV2: NADH dehydrogenase flavoprotein 2,
24 kDa; NDUFV3: NADH dehydrogenase flavoprotein 3, 10 kDa; OXA1 L: Oxidase (cytochrome c) assembly
1-like; PPA1: Pyrophosphatase 1; PPA2: Pyrophosphatase 2; SDHA: Succinate dehydrogenase complex, subunit
A, flavoprotein (Fp); SDHB: Succinate dehydrogenase complex, subunit B, iron sulfur (Ip); SDHC: Succinate
dehydrogenase complex, subunit C, integral membrane protein, 15 kDa; SDHD: Succinate dehydrogenase complex,
subunit D, integral membrane protein; UQCR11: Ubiquinol-cytochrome c reductase, complex III subunit XI; UQCRC1:
Ubiquinol-cytochrome c reductase core protein I; UQCRC2: Ubiquinol-cytochrome c reductase core protein II;
UQCRFS1: Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1; UQCRH: Ubiquinol-cytochrome c
reductase hinge protein; UQCRQ: Ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5 kDa.
Of note, compared with Healthy HDFs, Inflamed HDFs had upregulated ATP4A and ATP6V0A2
genes and downregulated COX6C gene. These genes encode enzymes belonging to ATP synthase
and CCO, respectively, which are fundamental for energy production and oxidative phosphorylation.
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The remaining 81 investigated genes were expressed at similar levels in both conditions. Compared
with Inflamed cells, no treatment altered the expression of these genes.
Compared with Inflamed HDFs, cells treated with Light overexpressed two genes belonging to
CCO: COX4I2 and COX8C. These genes remained unchanged in both cell group treated with FLE.
Genes belonging to complex I (NADH-Coenzyme Q Reductase), complex II (Succinate-Coenzyme
Q Reductase), and complex III (Coenzyme Q-Cytochrome c Reductase) maintained the same expression
profile in all the conditions investigated.
Table 2 reports the expression profiles of 84 genes related to biogenesis and function of mitochondria,
including regulators and mediators of mitochondrial molecular transport of metabolites required for
the electron transport chain and oxidative phosphorylation.














AIFM2 1.17 0.9186 1.05 0.9694 1.15 0.8808 1.05 0.3564
AIP −1.12 0.9070 1.16 0.8602 1.21 0.9389 1.13 0.8818
BAK1 2.18 0.4666 −1.09 0.8772 1.02 0.7111 −1.05 0.1289
BBC3 −2.91 0.9816 1.31 0.9722 1.08 0.9145 1.04 0.6868
BCL2 1.93 0.4330 1.13 0.4945 1.14 0.4947 1.16 0.5045
BCL2L1 −1.37 0.9929 1.07 0.4951 −1.07 0.3020 −1.07 0.3250
BID 1.51 0.6882 1.01 0.8719 1.06 0.9178 −1.35 0.2987
BNIP3 −1.36 0.8372 1.06 0.9668 −1.23 0.9024 −1.16 0.9280
CDKN2A −2.99 0.7208 −1.03 0.5949 1.13 0.3788 −1.23 0.3111
COX10 −1.03 0.6641 1.01 0.4646 −1.10 0.5937 −1.08 0.3185
COX18 −1.36 0.7253 1.32 0.6170 1.30 0.4723 1.09 0.3871
CPT1B −1.33 0.8146 0.99 0.9582 1.82 0.9127 2.04 0.4682
CPT2 1.11 0.6167 1.11 0.5475 1.04 0.4144 −1.03 0.3732
DNM1L 1.04 0.6504 1.02 0.4551 −1.02 0.3857 1.01 0.3536
FIS1 −1.29 0.7077 1.12 0.4843 1.15 0.4490 1.07 0.3857
GRPEL1 1.40 0.9575 −1.15 0.8785 −1.12 0.3880 −1.01 0.8202
HSP90AA1 −1.19 0.8602 1.06 0.5892 1.13 0.1296 1.27 0.4059
HSPD1 −1.17 0.8993 −1.01 0.9746 1.00 0.9350 1.07 0.8728
IMMP1L −2.51 0.9134 −1.02 0.9908 1.06 0.9928 1.10 0.9780
IMMP2L −1.31 0.5724 1.08 0.9491 1.08 0.9692 1.06 0.4700
LRPPRC −1.20 0.9990 1.19 0.7798 1.07 0.6555 1.10 0.6068
MFN1 −1.07 0.7624 1.05 0.9604 1.11 0.8119 1.10 0.5266
MFN2 −1.09 0.9807 −1.11 0.7044 −1.15 0.5278 −1.06 0.5023
MIPEP −1.84 0.9939 −1.03 0.8895 1.23 0.9541 1.26 0.4258
MPV17 −1.56 0.9050 1.05 0.9991 1.06 0.9772 1.04 0.5992
MSTO1 1.04 0.9795 1.10 0.9732 1.26 0.6936 1.17 0.3500
MTX2 1.01 0.4066 1.07 0.4383 1.33 0.2515 1.28 0.1868
NEFL 16.93 0.6088 −1.36 0.9775 −1.65 0.4401 −1.51 0.3560
OPA1 −1.20 0.5516 1.15 0.9987 1.10 0.6269 1.15 0.9292
PMAIP1 −1.06 0.8934 −1.01 0.9052 −1.24 0.9505 −1.03 0.9594
RHOT1 −1.42 0.8552 1.13 0.6221 1.20 0.4302 1.17 0.3495
RHOT2 1.07 0.7768 1.03 0.5066 1.00 0.5196 1.00 0.9821
SFN −2.38 0.4837 1.66 0.8181 1.90 0.4771 1.75 0.4248
SH3GLB1 −1.22 0.9383 1.28 0.9551 1.52 0.8607 1.52 0.3748
SLC25A1 −2.07 0.8876 1.13 0.8759 1.05 0.7808 1.04 0.7874
SLC25A10 1.38 0.6742 −1.62 0.9591 −1.85 0.9908 −1.60 0.9927
SLC25A12 −1.26 0.8391 −1.36 0.9808 −1.22 0.9588 −1.12 0.3523
SLC25A13 1.51 0.8949 1.11 0.9549 −1.05 0.9313 1.09 0.3061
SLC25A14 1.13 0.5778 1.06 0.9728 1.04 0.9826 1.03 0.2791
SLC25A15 1.20 0.6720 −1.02 0.5093 1.18 0.4814 1.21 0.3807
SLC25A16 −1.12 0.9002 1.13 0.8996 1.03 0.8461 1.16 0.6215















SLC25A17 1.26 0.8423 −1.05 0.9918 −1.10 0.8879 −1.06 0.5068
SLC25A19 1.44 0.8739 −1.08 0.9144 −1.07 0.8900 −1.06 0.9309
SLC25A2 1.14 0.6760 1.17 0.4763 1.15 0.4239 1.48 0.3471
SLC25A20 −1.19 0.8596 −1.14 0.7744 1.05 0.8105 1.05 0.5398
SLC25A21 −1.42 0.8432 0.99 0.5065 1.30 0.5826 1.43 0.3696
SLC25A22 1.21 0.7463 1.07 0.6007 1.11 0.6098 1.17 0.3715
SLC25A23 −1.43 0.7167 −1.09 0.4906 −1.52 0.4234 −1.27 0.3587
SLC25A24 −1.13 0.8747 1.05 0.8545 1.02 0.9513 1.03 0.3730
SLC25A25 2.30 0.9570 −1.06 0.9910 −1.11 0.8293 −1.09 0.6173
SLC25A27 −1.27 0.3919 −2.25 0.9605 −1.10 0.4895 −1.55 0.7273
SLC25A3 −1.20 0.3646 1.02 0.7269 1.03 0.4790 1.01 0.1843
SLC25A30 −1.36 0.9004 1.12 0.9875 1.08 0.9820 1.10 0.9916
SLC25A31 −1.12 0.8581 1.28 0.9795 2.47 0.9464 −1.06 0.4897
SLC25A37 1.92 0.6504 1.07 0.9261 1.21 0.8353 1.24 0.8423
SLC25A4 −1.86 0.6059 1.06 0.8584 −1.03 0.6999 1.02 0.8379
SLC25A5 1.00 0.9160 −1.09 0.5923 1.01 0.5904 1.05 0.3863
SOD1 −1.14 0.6756 1.09 0.4430 1.08 0.4504 1.14 0.3994
SOD2 17.28 0.8853 1.28 0.7959 1.19 0.7786 1.13 0.7637
STARD3 −1.04 0.3845 1.00 0.8834 −1.02 0.9115 1.01 0.9488
TAZ −1.26 0.8577 1.02 0.3116 1.27 0.2549 1.22 0.9748
TIMM10 1.22 0.8033 −1.08 0.5207 −1.09 0.4573 1.03 0.3611
TIMM10B 1.14 0.7175 1.06 0.9674 1.01 0.6375 −1.01 0.7582
TIMM17A 1.22 0.7552 −1.08 0.7767 1.05 0.7586 1.01 0.7073
TIMM17B −1.33 0.7433 1.29 0.5761 1.15 0.5304 1.23 0.4434
TIMM22 −1.06 0.7358 −1.08 0.4982 1.00 0.4019 1.17 0.3696
TIMM23 1.07 0.9080 −1.05 0.9481 1.00 0.9475 −1.01 0.7871
TIMM44 1.13 0.7086 −1.06 0.5628 −1.14 0.7906 −1.13 0.3392
TIMM50 −1.06 0.9866 1.09 0.8853 1.00 0.9968 1.09 0.8634
TIMM8A 1.28 0.7994 −1.11 0.1517 −1.05 0.2349 −1.01 0.2730
TIMM8B −1.11 0.9864 −1.06 0.9095 −1.09 0.8707 1.02 0.9847
TIMM9 1.37 0.6803 −1.14 0.6204 −1.29 0.4490 −1.33 0.3385
TOMM20 1.07 0.9647 1.00 0.9962 −1.05 0.9785 −1.03 0.9860
TOMM22 −1.03 0.9395 −1.03 0.9564 −1.05 0.9226 1.00 0.8254
TOMM34 1.16 0.9339 1.04 0.9646 0.99 0.9878 1.08 0.9486
TOMM40 1.29 0.5140 −1.16 0.6759 −1.09 0.8690 0.99 0.7455
TOMM40L −1.01 0.9861 1.13 0.8819 1.05 0.6619 1.15 0.3629
TOMM70A −1.16 0.9512 1.07 0.9631 1.19 0.8725 1.17 0.3903
TP53 −2.04 0.7434 1.44 0.8865 1.27 0.5986 −1.05 0.3399
TSPO −1.30 0.8269 1.10 0.5675 1.02 0.4945 1.00 0.3463
UCP1 −1.52 0.8095 3.89 0.8001 −1.09 0.6418 2.70 0.3743
UCP2 −1.52 0.9517 1.10 0.9361 1.08 0.8185 1.09 0.3625
UCP3 1.59 0.7862 1.64 0.6184 −1.31 0.5903 1.48 0.4868
UXT 1.07 0.9794 1.09 0.6893 1.05 0.8536 1.02 0.4300
AIFM2: Apoptosis-inducing factor, mitochondrion-associated, 2; AIP: Aryl hydrocarbon receptor interacting protein;
BAK1: BCL2-antagonist/killer 1; BBC3: BCL2 binding component 3; BCL2: B-cell CLL/lymphoma 2; BCL2L1:
BCL2-like 1; BID: BH3 interacting domain death agonist; BNIP3: BCL2/adenovirus E1B 19 kDa interacting protein 3;
CDKN2A: Cyclin-dependent kinase inhibitor 2A; COX10: COX10 homolog, cytochrome c oxidase assembly protein;
COX18: COX18 cytochrome c oxidase assembly homolog; CPT1B: Carnitine palmitoyltransferase 1B; CPT2: Carnitine
palmitoyltransferase 2; DNM1L: Dynamin 1-like; FIS1: Fission 1; GRPEL1: GrpE-like 1, mitochondrial; HSP90AA1:
Heat shock protein 90 kDa alpha, class A member 1; HSPD1: Heat shock 60 kDa protein 1; IMMP1L: IMP1 inner
mitochondrial membrane peptidase-like; IMMP2L: IMP2 inner mitochondrial membrane peptidase-like; LRPPRC:
Leucine-rich PPR-motif containing; MFN1: Mitofusin 1; MFN2: Mitofusin 2; MIPEP: Mitochondrial intermediate
peptidase; MPV17: MpV17 mitochondrial inner membrane protein; MSTO1: Misato homolog 1; MTX2: Metaxin 2;
NEFL: Neurofilament, light polypeptide; OPA1: Optic atrophy 1; PMAIP1: Phorbol-12-myristate-13-acetate-induced
protein 1; RHOT1: Ras homolog gene family, member T1; RHOT2: Ras homolog gene family, member T2; SFN:
Stratifin; SH3GLB1: SH3-domain GRB2-like endophilin B1; SLC25A1: Solute carrier family 25 (mitochondrial carrier;
citrate transporter), member 1; SLC25A10: Solute carrier family 25, member 10; SLC25A12: Solute carrier family
25, member 12; SLC25A13: Solute carrier family 25, member 13; SLC25A14: Solute carrier family 25, member 14;
SLC25A15: Solute carrier family 25, member 15; SLC25A16: Solute carrier family 25, member 16; SLC25A17: Solute
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carrier family 25, member 17; SLC25A19: Solute carrier family 25, member 19; SLC25A2: Solute carrier family
25, member 2; SLC25A20: Solute carrier family 25, member 20; SLC25A21: Solute carrier family 25, member 21;
SLC25A22: Solute carrier family 25, member 22; SLC25A23: Solute carrier family 25, member 23; SLC25A24: Solute
carrier family 25, member 24; SLC25A25: Solute carrier family 25, member 25; SLC25A27: Solute carrier family 25,
member 27; SLC25A3: Solute carrier family 25, member 3; SLC25A30: Solute carrier family 25, member 30; SLC25A31:
Solute carrier family 25, member 31; SLC25A37: Solute carrier family 25, member 37; SLC25A4: Solute carrier family
25, member 4; SLC25A5: Solute carrier family 25, member 5; SOD1: Superoxide dismutase 1; SOD2: Superoxide
dismutase 2; STARD3: StAR-related lipid transfer (START) domain containing 3; TAZ: Tafazzin; TIMM10: Translocase
of inner mitochondrial membrane 10 homolog; TIMM10B: Fracture callus 1 homolog; TIMM17A: Translocase
of inner mitochondrial membrane 17 homolog A; TIMM17B: Translocase of inner mitochondrial membrane 17
homolog B; TIMM22: Translocase of inner mitochondrial membrane 22 homolog; TIMM23: Translocase of inner
mitochondrial membrane 23 homolog; TIMM44:Translocase of inner mitochondrial membrane 44 homolog; TIMM50:
Translocase of inner mitochondrial membrane 50 homolog; TIMM8A: Translocase of inner mitochondrial membrane
8 homolog A; TIMM8B: Translocase of inner mitochondrial membrane 8 homolog B; TIMM9: Translocase of
inner mitochondrial membrane 9 homolog; TOMM20: Translocase of outer mitochondrial membrane 20 homolog;
TOMM22: Translocase of outer mitochondrial membrane 22 homolog; TOMM34: Translocase of outer mitochondrial
membrane 34; TOMM40: Translocase of outer mitochondrial membrane 40 homolog; TOMM40L: Translocase of
outer mitochondrial membrane 40 homolog-like; TOMM70A: Translocase of outer mitochondrial membrane 70
homolog A; TP53: Tumor protein p53; TSPO: Translocator protein (18 kDa); UCP1: Uncoupling protein 1; UCP2:
Uncoupling protein 2; UCP3: Uncoupling protein 3; UXT: Ubiquitously-expressed transcript.
Compared to Healthy cells, Inflamed HDFs showed substantial upregulation of superoxide
dismutase 2 (SOD2) and neurofilament (NEFL) genes. SOD2 is an antioxidant enzyme that protects
cells from oxidative damage, whereas NEFL influences the dynamics of mitochondria. Although to a
lesser extent, an upregulation of BCL2-antagonist/killer 1 (BAK1) and solute carrier family 25, member
25 (SLC25A25) and a downregulation of BCL2 binding component 3 (BBC3), Cyclin-dependent kinase
inhibitor 2A (CDKN2A), IMP1 inner mitochondrial membrane peptidase-like (IMMP1L), stratifin (SFN),
solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 (SLC25A1), and tumor
protein p53 (PT53) were also observed. The BAK1 gene encodes a pro-apoptotic protein. SLC25A25
and SLC25A1 genes encode proteins belonging to the family of calcium-binding mitochondrial carriers
in the inner membranes of the mitochondria. Their functions are to transport proteins, metabolites,
nucleotides and cofactors through the mitochondrial membrane and thereby connect and/or regulate
cytoplasm and matrix functions [46]. The SFN gene encodes the stratifin protein, a cell cycle checkpoint
protein that binds translation and initiation factors and functions as a regulator of mitotic translation.
It also regulates signal transduction pathways and cellular trafficking [47]. Cyclin-dependent kinase
inhibitor 2A (CDKN2A) is an inhibitor of CDK4 kinase and arrests the cell cycle in G1 phase [48]. The
BBC3 gene encodes the pro-apoptotic protein PUMA that is regulated by the protein tumor suppressor
p53 [49]. The PT53 gene encodes p53 protein that exhibits diverse and global functions, including cell
cycle arrest, senescence, and apoptosis. Through these pathways, p53 facilitates the repair and survival
of damaged cells or eliminates severely injured cells from the replicative pool to protect the organism.
One of the most dramatic responses to p53 activation is the induction of apoptosis [50]. No treatment
altered any of the above-mentioned genes compared with Inflamed HDFs.
Of interest, an upregulation of genes involved in the production of ATP and reduction of ROS was
observed. Compared to Inflamed cells, Light and FLE-Matrix treated HDFs showed an increase in UCP1
gene expression. This gene encodes uncoupling protein 1, a member of the family of mitochondrial
anion carrier proteins. The uncoupling proteins (UCPs) separate oxidative phosphorylation from ATP
synthesis with energy dissipated as heat, also referred to as mitochondrial proton leak. UCPs facilitate
the transfer of anions from the inner to the outer mitochondrial membrane and the return transfer of
protons from the outer to the inner mitochondrial membrane reducing the mitochondrial membrane
potential. A minor decline in the mitochondrial membrane potential leads to a significant decrease
in harmful levels of ROS production. UCPs proteins decrease mitochondrial membrane potential
to a level still allowing both production of required amounts of ATP, and of lower ROS levels that
would be relatively harmless to the cells [51]. Light treated cells also had a reduction in the expression
of SLC25A27, alias UCP4. Moreover, compared to Inflamed HDFs, FLE-Matrix treated cells had an
upregulation of CPT1B gene. Carnitine palmitoyltransferase-1 (CPT1) is located in the inner aspect
of the outer mitochondrial membrane and transports long-chain fatty acids into mitochondria for
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β-oxidation. The acetyl-coenzyme A (acetyl- CoA) produced by oxidative degradation of fatty acids
enters the citric acid cycle for oxidation to carbon dioxide and water by the electron transport chain
to yield ATP [52]. Compared to Inflamed cells, the FLE-Gel treated HDFs showed an increase in
SLC25A31 gene expression. The protein encoded by this gene is a member of the ADP/ATP carrier
family of proteins that exchange cytosolic ADP for matrix ATP in the mitochondria [53].
4. Discussion
In recent years, FLE has been demonstrated to be a safe and effective non-pharmacological
intervention for the treatment of acute and chronic wounds [23,37,39] and other skin pathologies [41,42],
however, the exact mechanism through which FLE realizes an acceleration in the wound healing
process is not yet clear.
The principle behind FLE is the absorption of photons by endogenous chromophores inside the
treated tissues, resulting in various biological effects [36]. It is widely known that mitochondria are
an initial site of light action in cells, and the central molecule for this is CCO, the terminal enzyme
of the mitochondrial respiratory chain. CCO transfers one electron (from each of four cytochrome c
molecules), to a single oxygen molecule, producing two molecules of water. At the same time the four
protons required are translocated across the mitochondrial membrane, producing a proton gradient
that ATP synthase uses to synthesize ATP [54]. CCO has two heme centers and two copper centers.
Each of these metal centers can exist in an oxidized or a reduced state, and each are photo-acceptors
with different absorption spectra in the red and near-infrared region (up to 950 nm). The absorption of
photons by CCO leads to an increase in enzymatic activity, an increase in oxygen consumption, and an
increase in ATP production thanks to the photodissociation of inhibitory nitric oxide (NO) [55]. Since
NO is non-covalently bound to the heme and copper centers and competitively blocks oxygen at a ratio
of 1:10, a relatively low energy photon can move the NO, allowing a lot of respiration to take place [56].
This theory describes the structural changes that CCO undergoes after exposure to photons.
Conversely, the present work aims to investigate the mitochondrial morphology and the expression
profile of genes related to the respiratory chain, and the mitochondrial dynamics and functions in
inflamed cells after the exposure to photons as either direct light (PBM) or FLE. For this purpose,
in vitro cultures of HDFs were stimulated overnight with a cocktail of pro-inflammatory cytokines
(TNFα/IL-1β) to induce an inflamed state. Then, Inflamed HDFs were treated with one of three different
photonic treatments: Light (a non-coherent light between 400 and 520 nm); FLE-Gel of FLE-Matrix (a
mix of non-coherent light and FLE with a broad spectrum between 400 and 700 nm). All Inflamed
and treated cells were maintained in the inflammatory cocktail environment post-treatment for the
duration of the experiment.
Thirty minutes post-treatments, confocal microscopy analysis showed mitochondrial
fragmentation in Inflamed HDFs and Light treated cells. Likewise, Motori and colleagues have
previously shown that pro-inflammatory stimuli produced localized changes in mitochondrial
dynamics, favoring fission over fusion [57]. Indeed, the mitochondrial architecture of a cell results
from movement, tethering, fusion and fission events. Owing to frequent fission and fusion, different
shapes of mitochondria can be found within a cell, including small vesicles, short rods, and long
reticular networks. Strong evidence has demonstrated that mitochondrial dynamics are important for
cell viability, senescence, mitochondria health, bioenergetic function, quality control, and intracellular
signaling. Shortening of mitochondria is a result of increased fission activity or decreased fusion
activity, and is typical for states of reduced bioenergetic efficiency (increased respiratory leak) [58].
Fragmentation of mitochondria may also indicate activation of the autophagic removal of
mitochondria by a process known as mitophagy. This process is described as a pro-survival mechanism
employed as an early response to cell stress, since it removes damaged mitochondria. Contrarily, if
unfavorable condition persists, mitophagy results in cell death. Changes in mitochondrial morphology
also occur in the early step of the cell death mechanisms apoptosis and necrosis [59,60]. The progressive
loss of mitochondrial network during exposure to inflammatory mediators affirms that chronic
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inflammation affects mitochondrial morphology and bioenergetic functions. Of note, even as early
as 30-min post-treatment, FLE-treated cells were starting to progress toward a healthier state of
mitochondria, with significant differences observed between Inflamed HDFs and FLE-treated HDFs in
the number of mitochondria per cell and the individual mitochondrion volume.
A full recovery of mitochondrial network occurred by 24-h post-treatment with FLE, manifested
by mitochondrial networks comparable to those of Healthy HDFs. A trend towards recovery was also
observed with Light-treated cells (PBM), however, while there were no significant differences from
Healthy HDFs for mitochondria morphology, only the individual mitochondrion volume was different
between Inflamed and Light-treated HDFs. This improved biological effect of FLE compared with
PBM has been previously observed [36,40]. While not clearly understood, a possible explanation is
biological sensitivity to changes in the light properties that arise during generation of FLE, including
polarity, micro-pulsations, or coherency. Of note, opsin proteins are known to be sensitive to light
polarity, thus it is feasible that other endogenous chromophores, including CCO, may be as well [61].
This enhanced impact of FLE compared with Light treatment is clearly visible in the radial graphs
(Figure 3), with FLE-treated HDFs demonstrating both a quicker and more potent recovery.
Interestingly, we may see a dose-response starting to occur between FLE-Gel and FLE-Matrix.
At 30-min, both groups have almost identical mitochondrial dynamics, however, by 24 h it appears
as if the FLE-Matrix may be shifting the mitochondria network balance further towards fusion, even
beyond that of the Healthy HDFs. However, there is no statistical significance to this finding, so
further studies would be needed to better understand any dose effects associated with FLE and its
biological implication. It is known that processes associated with increased energy are characterized by
mitochondrial elongation and by respiration coupled to ATP synthesis [58]. We can hypothesize that
the absorption of low energy photons by CCO has led to a restoration of the mitochondrial network
due to an increase in enzymatic activity and respiration, and therefore an increase in ATP production.
Gene expression analysis did not report great alterations in expression of genes encoding enzymes
of respiratory chain. In Light-treated cells, compared to Inflamed HDFs, upregulation of COX4I2,
COX8C and UCP1 genes was observed. Little is reported about the expression of these genes in the
literature, and nothing about their expression during the inflammatory process. However, Suárez
and workers linked the upregulation of COX4I2 gene to the increase in UCP1 expression in an obese
animal model [62]. They demonstrated that the overexpression of the thermogenic factor UCP1
improves metabolic phenotype concurrent with mitochondrial biogenesis trough the COX4I2 gene
overexpression. In Light-treated cells, the improvement in mitochondrial biogenesis due to the
upregulation of CCO-coding genes could be the basis of the mitochondrial morphology recorded 24
h post-treatment. In fact, through an increase in the number of mitochondria, a restoration of the
mitochondrial volume equal to healthy cells has been observed. Conversely, in Inflamed cells, where
COX6C gene downregulation was recorded, drastic mitochondrial fragmentation and a decrease in
whole mitochondrial volume were found.
It was demonstrated that TNF-α and IL-1β decrease ATP production by reducing the activity of
complex I, as well as by reducing mitochondrial membrane potential and inducing mitochondrial DNA
damage [63]. The damage and mutations of mitochondrial DNA lead to the synthesis of functionally
impaired respiratory chain subunits, promoting increased ROS production. In Inflamed cells, the
increased production of ROS was confirmed by the upregulation of SOD2, the main mitochondrial
antioxidant enzyme. It has been reported that when the inflammatory signal through the NF-κB
pathway is strong and extended, the SOD2 expression is upregulated to maintain ROS homeostasis.
However, if the ROS level is not restrained, cell damage and death occur [64]. In Light-treated
cells, the levels of ROS are controlled by UCP1 upregulation via a slight decline in mitochondrial
membrane potential, however allowing the production of ATP [44]. Since UCP1 was recently found
deregulated during inflammation [65], and essential to preserve mitochondrial structural integrity and
function [66,67], we can speculate that Light treatment may improve the mitochondrial function and
recover mitochondrial network by the upregulation of this protein.
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Instead, treatment with FLE-Matrix resulted in upregulation of UCP1 as well as CTP1B, which is
involved in mitochondrial β-oxidation of lipids long-chain fatty acids. Both genes are linked to an
increase in ATP production because UCP separates oxidative phosphorylation from ATP synthesis
allowing the production of ATP, also in the presence of ROS. Instead CTP1 favors β-oxidation of lipids
ensuring the production of ATP [51,52]. It has already been shown that an increase in ATP synthesis is
connected with the mitochondrial elongation under different cell conditions [58]. Compared to Light
treatment, FLE-Matrix increased the volume of whole mitochondrial network through an increase in
the volume of single mitochondria, favoring mitochondrial elongation. Having found the highest
mitochondrial network recovery in this condition, we can assume that the gain in ATP production by
mitochondrial β-oxidation may help in restoration of mitochondrial dynamics.
Conversely, an increase in UCP1 and CTP1B expression was not found in FLE-Gel treated cells,
but an increase in SLC25A31 gene expression was observed. This gene encodes a nucleotide transporter
which imports ADP into the mitochondrial matrix, where it can be converted to ATP by ATP synthase,
and then exports the newly synthesized ATP to the cytosol [68]. Therefore, this carrier protein plays
an important role in spending the ATP on metabolic processes necessary for cell survival. Since both
FLE-Gel and FLE-Matrix recover mitochondrial network, it can be hypothesized that upregulation of
this mitochondrial carrier causes an increase in ATP production due to the activation of ATP synthase.
ATP is the cellular energy-carrying molecule essential for multiple cellular functions. Reduced
energy levels threaten cellular homeostasis and integrity. Impaired energy metabolism may trigger
pro-apoptotic signaling, oxidative damage, cytotoxicity and impede mitochondrial DNA repair [69].
All the evaluated treatments led to an improvement in intracellular ATP levels, thus energizing the
cells. However, it seems that FLE treatment rescued inflamed mitochondrial networks, returning
them to a healthy condition despite the presence of oxidative stress caused by continued exposure to
TNFα/IL-1β inflammatory cytokines. This return of mitochondrial homeostasis by FLE could be a key
mechanism supporting accelerated healing and tissue regeneration in wounds and skin pathologies
treated with FLE.
5. Conclusions
In conclusion, this work investigated the effect of FLE on mitochondrial homeostasis in an in vitro
model of inflammation. FLE treatment leads to restoration of the mitochondrial network by 24-h
post-treatment, as well as upregulation of UCP1 and CPT1B genes, which encode proteins favoring
the production of ATP through oxidative phosphorylation and lipid β-oxidation, respectively. These
observations, coupled with the previously established capacity of PBM to stimulate CCO, show a
beneficial effect of FLE in the treatment of inflamed wounds. However, these findings derive from an
in vitro model and should be validated by an in vivo investigation.
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